Journal
DERMATOLOGIC THERAPY
Volume 34, Issue 1, Pages -Publisher
WILEY-HINDAWI
DOI: 10.1111/dth.14660
Keywords
infection; interleukin‐ 17; interleukin‐ 23; psoriasis; psoriatic arthritis; SARS‐ CoV‐ 2
Categories
Ask authors/readers for more resources
Psoriasis is a chronic immune-mediated disease that requires lifelong treatment to control symptoms, as there is no cure available. Research interest is high in the newest biological drugs for treating moderate to severe psoriasis, especially those that block the IL-23/IL-17 axis.
Psoriasis is a chronic immune-mediated disease characterized by inflammation of skin (psoriasis) or joints (psoriatic arthritis) or both, resulting from a dysregulation in particular of the T helper (Th)17 functions. There is no available cure for psoriasis, and a life-long treatment is needed to control signs and symptoms. Research interest is high around the newest biological drugs approved for the treatment of moderate to severe psoriasis and psoriatic arthritis, and especially drugs blocking the IL-23/IL-17 axis. Our aim is to review the new biological drugs for the treatment of psoriasis and their adverse effects, focusing on the risk of infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available